Artificial intelligence continues to revolutionize biotechnology, with major strides in drug design, genomics, and medical imaging. Google DeepMind’s AlphaGenome introduces a unified AI model predicting how DNA sequence variations influence gene regulation, enhancing understanding of gene activity changes at scale. Concurrently, Gero’s ProtoBind-Diff offers a sequence-conditioned molecular generation tool to design drug-like ligands without structural data, broadening target ligandability. Researchers at The City College of New York and Memorial Sloan Kettering Cancer Center unveiled an open-source AI model that markedly improves breast cancer detection and tumor localization in MRI images, tackling limitations of traditional methods. SandboxAQ launched SAIR, a public dataset comprising over 5 million protein-ligand binding structures to facilitate AI training in molecular binding prediction. Collectively, these AI-driven breakthroughs promise to accelerate drug discovery and precision medicine applications.